[go: up one dir, main page]

DK3421051T3 - Fremgangsmåder til glycokonjugering og sammensætninger - Google Patents

Fremgangsmåder til glycokonjugering og sammensætninger Download PDF

Info

Publication number
DK3421051T3
DK3421051T3 DK18183661.0T DK18183661T DK3421051T3 DK 3421051 T3 DK3421051 T3 DK 3421051T3 DK 18183661 T DK18183661 T DK 18183661T DK 3421051 T3 DK3421051 T3 DK 3421051T3
Authority
DK
Denmark
Prior art keywords
glycoconjugation
compositions
methods
Prior art date
Application number
DK18183661.0T
Other languages
English (en)
Inventor
Jianxin Gu
Jin-Hwan Kim
Krishna A Prasad
Yu-Ying Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3421051T3 publication Critical patent/DK3421051T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DK18183661.0T 2012-08-16 2013-08-12 Fremgangsmåder til glycokonjugering og sammensætninger DK3421051T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261684043P 2012-08-16 2012-08-16
EP13779365.9A EP2885007B1 (en) 2012-08-16 2013-08-12 Glycoconjugation processes and compositions

Publications (1)

Publication Number Publication Date
DK3421051T3 true DK3421051T3 (da) 2020-06-22

Family

ID=49385307

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13779365.9T DK2885007T3 (da) 2012-08-16 2013-08-12 Fremgangsmåder til glycokonjugering og sammensætninger
DK18183661.0T DK3421051T3 (da) 2012-08-16 2013-08-12 Fremgangsmåder til glycokonjugering og sammensætninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK13779365.9T DK2885007T3 (da) 2012-08-16 2013-08-12 Fremgangsmåder til glycokonjugering og sammensætninger

Country Status (32)

Country Link
US (6) US9517274B2 (da)
EP (2) EP2885007B1 (da)
JP (1) JP6291495B2 (da)
KR (1) KR101742406B1 (da)
CN (1) CN104661684B (da)
AR (1) AR092368A1 (da)
AU (1) AU2013303826B2 (da)
BR (1) BR112015003227B1 (da)
CA (1) CA2881420C (da)
DK (2) DK2885007T3 (da)
ES (2) ES2800479T3 (da)
FI (1) FIC20220032I1 (da)
FR (1) FR22C1037I2 (da)
HU (3) HUE041381T2 (da)
IL (1) IL237066B (da)
IN (1) IN2015DN00694A (da)
LU (1) LUC00273I2 (da)
MX (1) MX363511B (da)
MY (1) MY167579A (da)
NL (1) NL301188I2 (da)
NO (1) NO2022034I1 (da)
NZ (1) NZ704490A (da)
PE (1) PE20150464A1 (da)
PH (1) PH12015500243B1 (da)
PL (2) PL3421051T3 (da)
PT (2) PT2885007T (da)
RU (2) RU2645071C2 (da)
SA (1) SA515360035B1 (da)
SG (1) SG11201500566XA (da)
SI (2) SI2885007T1 (da)
TW (1) TWI480049B (da)
WO (1) WO2014027302A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881420C (en) 2012-08-16 2016-11-15 Pfizer Inc. Glycoconjugation processes and compositions
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP3096786B1 (en) * 2014-01-21 2021-07-07 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
CN105934251A (zh) * 2014-01-21 2016-09-07 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
HUE054034T2 (hu) 2014-03-13 2021-08-30 Univ Basel Mielin asszociált glikoprotein elleni IgM antitestekhez kapcsódó szénhidrát ligandumok
EP3244917B1 (en) 2015-01-15 2023-04-19 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MX368897B (es) * 2015-05-04 2019-10-21 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
EA201792470A1 (ru) * 2015-06-08 2018-10-31 Серум Инститьют Оф Индия Прайват Лтд. Способы улучшения адсорбции полисахарид-белковых конъюгатов и полученная из них композиция поливалентной вакцины
KR102800419B1 (ko) * 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
US11091591B2 (en) 2015-09-16 2021-08-17 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CA3031797A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3562503B1 (en) 2016-12-30 2025-04-23 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
DK3570879T3 (da) 2017-01-20 2022-04-11 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
WO2019050818A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. METHODS OF FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR102634811B1 (ko) * 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
EP3678655A4 (en) 2017-09-07 2021-05-05 Merck Sharp & Dohme Corp. PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
KR102812816B1 (ko) 2018-02-05 2025-05-27 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
EP3749357A4 (en) 2018-02-05 2022-04-20 Sanofi Pasteur, Inc. POLYVALENT PNEUMOCOCCAL POLYSACCHARIDE PROTEIN CONJUGATE COMPOSITION
CN111615400B (zh) * 2018-03-23 2025-05-02 科纳克斯资本 作为治疗工具的精确糖缀合物
KR20190121713A (ko) 2018-04-18 2019-10-28 에스케이바이오사이언스(주) 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
CN111024832B (zh) * 2019-10-29 2022-05-03 北京成大天和生物科技有限公司 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法
JP2021087420A (ja) 2019-11-01 2021-06-10 ファイザー・インク Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ組成物およびその方法
EP4107192A1 (en) 2020-02-21 2022-12-28 Pfizer Inc. Purification of saccharides
KR20220143910A (ko) 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
JP7630603B2 (ja) 2020-08-10 2025-02-17 インベントプライズ・インコーポレイテッド 出現血清型２４ｆを含む多価肺炎球菌複合糖質ワクチン
JP7481585B2 (ja) 2020-09-17 2024-05-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド 多価ワクチン組成物及びその使用
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4622665A2 (en) 2022-11-22 2025-10-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US578573A (en) 1897-03-09 Brake-actuating mechanism
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
WO1998056942A1 (en) 1997-06-12 1998-12-17 Shin-Etsu Bio, Inc. Production of non-native bacterial exopolysaccharide in a recombinant bacterial host
DK1117435T3 (da) 1998-09-30 2008-03-17 Wyeth Corp Muteret cholera-holotoxin som adjuvans
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
AP1897A (en) * 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN1394867A (zh) * 2001-07-06 2003-02-05 中国科学院生态环境研究中心 可作药物的寡糖和其制备方法及含该寡糖的药物组合物
AU2003277139A1 (en) * 2002-10-03 2004-04-23 Wyeth Holdings Corporation Process for preparing monoprotected diols from symmetric diols
KR20060035581A (ko) * 2003-03-07 2006-04-26 와이어쓰 홀딩스 코포레이션 병원내 감염에 대한 면역화에 유용한다당류-스타필로코커스 표면 부착소 운반체 단백질 접합체
CA2519511A1 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2313328T3 (es) * 2004-04-14 2009-03-01 Wyeth Procedimiento para la preparacion de 42-esteres de rapamicina y 32-esteres de fk-506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos.
US7910753B2 (en) * 2004-09-10 2011-03-22 Anaspec Incorporated Cyanine dyes and their applications as luminescence quenching compounds
CA2986862C (en) 2005-04-08 2022-09-27 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0513069D0 (en) * 2005-06-27 2005-08-03 Glaxosmithkline Biolog Sa Immunogenic composition
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR101441368B1 (ko) * 2005-12-22 2014-09-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 폐렴구균 다당류 컨쥬게이트 백신
TW200806685A (en) * 2006-02-21 2008-02-01 Wyeth Corp Processes for the convergent synthesis of calicheamicin derivatives
AR059740A1 (es) * 2006-03-07 2008-04-23 Wyeth Corp Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
DE102006026436A1 (de) * 2006-06-07 2007-12-13 Continental Aktiengesellschaft Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche
AU2008265767B2 (en) * 2007-06-20 2014-11-13 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
RU2378015C2 (ru) * 2008-04-02 2010-01-10 Равшан Иноятович Атауллаханов Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CA2766614C (en) * 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
AU2010324839B2 (en) * 2009-11-24 2015-02-19 Grifols Therapeutics Inc. Lyophilization methods, compositions, and kits
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
CN103945870B (zh) * 2011-09-07 2016-10-12 普罗林科斯有限责任公司 生物可降解交联的水凝胶
CA2881420C (en) * 2012-08-16 2016-11-15 Pfizer Inc. Glycoconjugation processes and compositions
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
ES2701169T3 (es) 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos

Also Published As

Publication number Publication date
IL237066B (en) 2019-03-31
AU2013303826B2 (en) 2017-06-29
RU2016136630A (ru) 2018-12-11
TW201420115A (zh) 2014-06-01
HUE041381T2 (hu) 2019-05-28
US20170224804A1 (en) 2017-08-10
LUC00273I2 (da) 2025-05-12
BR112015003227A2 (pt) 2017-07-04
NO2022034I1 (no) 2022-08-04
ES2800479T3 (es) 2020-12-30
HK1210021A1 (en) 2016-04-15
PL2885007T3 (pl) 2019-02-28
HUE049531T2 (hu) 2020-10-28
AU2013303826A1 (en) 2015-02-12
PH12015500243B1 (en) 2019-05-31
FR22C1037I1 (fr) 2022-09-09
TWI480049B (zh) 2015-04-11
HUS2200034I1 (hu) 2022-08-28
US9950054B2 (en) 2018-04-24
US20220096619A1 (en) 2022-03-31
CN104661684B (zh) 2018-03-20
PE20150464A1 (es) 2015-04-25
SI2885007T1 (sl) 2018-12-31
SG11201500566XA (en) 2015-04-29
MY167579A (en) 2018-09-20
MX363511B (es) 2019-03-26
IN2015DN00694A (da) 2015-06-26
BR112015003227B1 (pt) 2020-10-27
EP2885007A1 (en) 2015-06-24
US20180221467A1 (en) 2018-08-09
US20200246448A1 (en) 2020-08-06
PH12015500243A1 (en) 2015-03-30
CN104661684A (zh) 2015-05-27
PL3421051T3 (pl) 2020-10-05
RU2645071C2 (ru) 2018-02-15
CA2881420A1 (en) 2014-02-20
PT2885007T (pt) 2018-12-10
FR22C1037I2 (fr) 2023-05-26
ES2700824T3 (es) 2019-02-19
NZ704490A (en) 2017-07-28
EP3421051B1 (en) 2020-05-13
RU2724840C2 (ru) 2020-06-25
EP3421051A1 (en) 2019-01-02
US10583187B2 (en) 2020-03-10
FIC20220032I1 (fi) 2022-08-05
US12447203B2 (en) 2025-10-21
SA515360035B1 (ar) 2015-09-15
SI3421051T1 (sl) 2020-08-31
RU2016136630A3 (da) 2019-12-30
US20150216996A1 (en) 2015-08-06
US9517274B2 (en) 2016-12-13
MX2015001992A (es) 2015-10-05
KR101742406B1 (ko) 2017-05-31
JP2015524839A (ja) 2015-08-27
DK2885007T3 (da) 2018-12-03
US20230355735A1 (en) 2023-11-09
US11110160B2 (en) 2021-09-07
EP2885007B1 (en) 2018-10-10
JP6291495B2 (ja) 2018-03-14
CA2881420C (en) 2016-11-15
KR20150041139A (ko) 2015-04-15
WO2014027302A1 (en) 2014-02-20
RU2015103017A (ru) 2016-10-10
US11723965B2 (en) 2023-08-15
AR092368A1 (es) 2015-04-15
NL301188I2 (nl) 2024-05-15
PT3421051T (pt) 2020-06-26

Similar Documents

Publication Publication Date Title
FR22C1037I2 (fr) Procedes de glycoconjugaison et compositions
DK2884999T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK3363806T3 (da) Glycokonjugationsfremgangsmåde
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK2850202T3 (da) Fremgangsmåder og grupper
DK2861223T3 (da) Sammensætninger og metoder til transmukosal absorption
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK3363901T3 (da) Sammensætninger og fremgangsmåder til præcis identificering af mutationer
DK2890780T3 (da) Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand
DK2920167T3 (da) Hydrazinyl-indol-forbindelser og konjugater
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
DK2928921T3 (da) Sammensætninger og fremgangsmåder til antistoffer målrettet epo
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
DK2758349T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf
DK2877019T3 (da) Sikkerede herbisidiske sammensætninger til anvendelse i ris
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
EP2934454C0 (en) ANTI-DANDRUFF COMPOSITION
DK3930322T3 (da) Fremgangsmåder og anordninger til kodning
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK3381461T3 (da) Peptider og fremgangsmåder til anvendelse deraf